-
Precision Targeting in Drug Delivery: Unleash the Power of DSPE-PEG-MAL
July 10,2025.
Achieving precise delivery of therapeutic agents to specific cells remains a cornerstone of modern medicine. Unlock new levels of precision in ligand-mediated drug delivery with DSPE-PEG-MAL, a versat...
View More
-
DSPE-PEG-MAL empowers in vivo CAR-T: GMP-grade in stock, setting a new benchmark for targeted delivery
November 19,2025.
In the field of biomedicine, CAR-T therapy is undergoing a revolutionary leap from in vitro preparation to in vivo programming. The year 2025 marks a crucial turning point in the development of in viv...
View More
-
Unlocking in vivo CAR-T therapy with DSPE-PEG-MAL - A chemical bridge to the next generation of cell treatment
May 21,2026.
The revolution of in vivo CAR-T is here. After decades of impressive but logistically challenging ex vivo CAR-T, 2025 marks the turning point-Capstan’s CPTX2309 entered Phase I, and AbbVie acquired Ca...
View More
-
R&D News | Sinopeg’s Key Excipient for Nucleic Acid Drug Delivery, DSPE-PEG-MAL, Reaches Another Milestone – CDE Filing Completed!
June 8,2026.
Recently, Sinopeg’s LNP lipid excipient product, DSPE-PEG-MAL(NH4+)-2K, has successfully completed pharmaceutical excipient filing with the Center for Drug Evaluation (CDE) of the National Medical Pro...
View More
-
DSPE-PEG-OH | Sinopeg
July 17,2026.
DSPE-PEG-OH (Distearoyl Phosphatidylethanolamine-Polyethylene Glycol-Hydroxyl)is an amphiphilic block copolymer composed of a hydrophobic DSPE moiety, a hydrophilic PEG chain, and a terminal hydroxyl ...
Hot Tags :
- lipid
- mRNA
- DSPE
View More
Business WeChat
